Measuring quality of life changes in Parkinson's patients
Determination of the Minimal Detectable Change and Minimum Clinically Important Change Score of the Parkinson's Disease Questionnaire-8
This study is testing how much a 30-session physiotherapy program can improve the quality of life for people with Parkinson's disease by using a questionnaire to track changes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 39 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | Karadeniz Technical University Academic / other |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT06487364 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine the minimal detectable change in the Parkinson's Disease Questionnaire-8 (PDQ-8), which assesses the quality of life in patients with Parkinson's disease. Participants undergoing a 30-session physiotherapy program will report their quality of life changes before and after treatment using the PDQ-8 and Global Rating of Patient-Perceived Changes (GRP-PC) forms. The study will help establish how much improvement in PDQ-8 scores is considered significant for patients.
Who should consider this trial
Good fit: Ideal candidates include Parkinson's patients in stages 1-3 of the Hoehn and Yahr Scale who are receiving regular neurological follow-up and medication.
Not a fit: Patients with secondary neurological diseases, recent surgeries affecting the upper extremities, or significant psychological issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a clearer understanding of meaningful quality of life improvements for Parkinson's patients undergoing rehabilitation.
How similar studies have performed: While similar studies have explored quality of life measures in Parkinson's disease, this specific approach to determining minimal detectable change is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Having regular neurology follow-up and using medicine; * Hoehn and Yahr Scale Stage between 1-3 points; * Mini-Mental State Assessment Score \>24 points; Exclusion Criteria: * Having a secondary neurological disease; * Any surgery and/or trauma affecting the upper extremity * Having complaints of pain before the treatment program; * There was a change in medical treatment during the study; * With symptoms of anxiety and depression; * Those who use alcohol and drugs; * Individuals with vision defects that cannot be corrected by the use of glasses and those with hearing loss
Where this trial is running
Istanbul
- Private Güney Hospital — Istanbul, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Emre Şenocak, PhD
- Email: emre.senocak@windowslive.com
- Phone: +90 553 569 56 92
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.